Syran

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Syran

What is Syran? Definition and Classification Overview

Property Description
Active Ingredient Ciprofloxacin
Primary Form Tablet (also Injection, Drops)
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose Bacterial Infection Elimination
Origin Synthetic Compound

What is Syran? Definition and Pharmacological Classification

Syran is the trade name for the synthetic antimicrobial agent Ciprofloxacin, which is officially classified as a second-generation fluoroquinolone antibiotic. This medication belongs to the broader family of quinolone antibiotics, powerful drugs utilized specifically to eliminate illnesses caused by bacterial pathogens.

The active ingredient, Ciprofloxacin, is a chemically manufactured compound, making it a synthetic medicine rather than one derived from natural sources. The compound is typically formulated as the salt Ciprofloxacin hydrochloride or the base Ciprofloxacin betaine. Syran offers the same core formulation as its generic counterparts, ensuring therapeutic equivalence in the elimination of susceptible bacteria. This pharmacological class is utilized when a highly effective, established agent is required to treat infections.


Composition, Forms, and General Purpose

Syran is a single active ingredient product designed to eliminate bacteria via a powerful bactericidal action, ensuring the pathogen is killed rather than merely inhibited. The general purpose of this medicine is to address and resolve infections by directly causing bacterial death, frequently being employed in scenarios requiring systemic clearance.


The medicine is available in multiple dosage form(s), providing clinical flexibility for various treatment needs. These forms include standard and extended-release tablets for oral use, an oral liquid (suspension), a solution for intravenous injection, and specialized topical solutions such as eye drops (ophthalmic solution) and ear drops (otic solution). This broad range of routes of administration ensures the active ingredient, Ciprofloxacin, can be effectively delivered to the precise location of the infection.

Regulatory References

  1. MedlinePlus Drug Information on Ciprofloxacin

What side effects are possible with Syran?

Possible Side Effects and Safety Information

The official safety profile for Syran (Ciprofloxacin) is structured by governmental regulatory bodies, classifying potential reactions by frequency and the body system affected. Common (ge 1/100) adverse reactions documented in regulatory sources primarily involve gastrointestinal disturbances, such as nausea and diarrhea, alongside changes in liver function tests.


Serious Adverse Reactions and Key Warnings

Official labeling highlights several serious adverse reactions, which may be potentially irreversible. These include Tendonitis and Tendon Rupture, a major safety concern noted in the Boxed Warning of the U.S. label, which can occur during or up to several months after treatment. Other serious reactions involve the Nervous System, such as seizures and Peripheral Neuropathy (nerve damage, potentially causing pain, burning, or tingling), and cardiovascular risks like Aortic Aneurysm and Dissection.


Population-Specific and Time-Related Safety

Safety data specify that older adults have an officially recognized increased risk for severe tendon problems. Similarly, pediatric patients (under 18) show an elevated incidence of musculoskeletal issues. Regulatory documents also state that the medicine should be avoided in individuals with a history of Myasthenia Gravis due to the risk of exacerbating muscle weakness. Treatment is formally restricted in certain circumstances, such as co-administration with Tizanidine, which is strictly contraindicated.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Syran, a potent opioid analgesic, is a medical emergency that can be fatal if not immediately addressed. The primary danger of Syran overdose is severe respiratory depression, where breathing becomes extremely shallow, slow, or stops entirely, leading to hypoxia and death.

Key signs and symptoms of a serious overdose, documented in regulatory profiles, constitute a triad of effects:

  • Central Nervous System (CNS) Depression: Profound sleepiness, stupor, or coma, where the individual cannot be awakened or respond to verbal stimuli.
  • Respiratory Compromise: Marked reduction in breathing rate and depth, which may be accompanied by gurgling sounds, or complete respiratory arrest.
  • Miosis: Pupils that are constricted to the size of a pinpoint.

Other clinical manifestations may include skeletal muscle flaccidity, cold and clammy skin, and progression to circulatory depression, shock, and cardiac arrest.

The risk of life-threatening respiratory depression is significantly increased when Syran is taken in combination with other central nervous system depressants, such as alcohol or benzodiazepines. Overdose risk is also noted to increase as the opioid dosage increases.

When to Seek Immediate Emergency Help

Immediate emergency medical attention (e.g., calling 911 or local emergency services) is mandatory if an overdose is suspected or if any of the following symptoms occur: profound sedation, difficulty waking the individual, slowed or stopped breathing, pale or blue lips/fingernails, or inability to speak. Prompt action and the administration of an opioid antagonist (such as naloxone) are required to reverse the effects and prevent a fatal outcome.

Therapeutic Uses of Syran

What Syran Treats: Main Uses and Benefits

Syran is used to help relieve the uncomfortable and persistent symptoms related to systemic imbalance—such as fever, pain, and localized discomfort—that are generally caused by bacterial infections. This medication is relevant for easing symptoms that interfere with daily comfort across conditions presenting with acute episodes. It is commonly applied in scenarios that require assistance with symptom stabilization when the patient experiences heightened discomfort.

It is used across various therapeutic domains to address bacterial infections, including those affecting the respiratory tract, the urinary tract, and the skin or soft tissues. This class of medicine helps address symptom clusters that may become intense or disruptive due to bacterial presence.

“This medication supports patients during difficult episodes by easing distress and helping them cope more steadily with their symptoms.”

By assisting with symptom control, Syran contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities. It may be part of symptomatic management in contexts involving temporary physiological imbalance.


Quick Fact: Relief for Fever and Localized Discomfort

Eligibility and Restrictions for Use

The decision to use Syran, which contains ciprofloxacin, is based on the specific bacterial infection being treated and the patient's full medical history. It is generally indicated for adults to treat various bacterial infections, including those of the respiratory, urinary, and gastrointestinal tracts, as well as skin, bone, and joint infections.

Syran is contraindicated and must not be used by individuals with a known allergy to ciprofloxacin or other quinolone antibiotics (such as moxifloxacin or levofloxacin). It is also strictly contraindicated in patients taking tizanidine (a muscle relaxant) due to the risk of significant drug interaction.


Certain conditions and populations require caution or make Syran use generally inadvisable:

Condition/Population Rationale for Caution/Avoidance
Children/Adolescents (under 18) Increased risk of joint and cartilage damage.
Pregnancy/Breastfeeding Potential harm to the developing fetus or infant.
History of Tendon Issues Increased risk of tendon rupture.
Epilepsy/Seizure Disorders Potential to lower the seizure threshold.
Myasthenia Gravis May worsen muscle weakness.
Heart Rhythm Disorders Risk of QT interval prolongation.
Kidney or Liver Impairment Dosage adjustment or avoidance may be necessary.

Patients should inform their healthcare provider of all medical conditions and other medications, including supplements, to assess the suitability of Syran treatment.

What should I know about interactions with other medicines?

Syran Interactions with other Medicines and Products: Official Regulatory Information

Syran (Ciprofloxacin) has documented interactions with other medicines and products, which are strictly classified in government regulatory labeling. These interactions primarily stem from the drug's properties as a CYP1A2 enzyme inhibitor and its ability to chelate multivalent cations in the digestive tract.


Official Interaction Classifications and Restrictions

Classification Interacting Substance/Product Regulatory Restriction
Contraindicated Tizanidine Administration is prohibited due to significantly increased Tizanidine exposure.
Pharmacokinetic (Reduced Absorption) Multivalent Cation-Containing Products (e.g., Antacids, Iron/Calcium supplements) Oral Syran must be administered hours apart from these products to prevent reduced drug absorption.
Pharmacokinetic (Increased Exposure) Theophylline, Ropinirole, Caffeine Plasma concentrations of these medicines are increased due to Syran's CYP1A2 inhibition.
Pharmacodynamic (Additive Risk) Warfarin, NSAIDs Requires enhanced monitoring for augmented anticoagulant effects (Warfarin) or increased risk of CNS stimulation (NSAIDs).
Population Note Geriatric Patients on Corticosteroids Increased risk for severe tendon disorders is noted.

The regulatory profile mandates careful management for several concomitant medicines. This includes required monitoring for drugs affected by CYP1A2 inhibition and strict timing separation rules for cation-containing products. These official constraints are documented to maintain therapeutic efficacy and manage specific interaction risks.

Mechanism of Action

How Syran Works

Syran (Ciprofloxacin) acts through a mechanism defined by its selective action on bacterial cells, primarily engaging two core biological domains within the pathogen.


Targeting Bacterial DNA Gyrase and Topoisomerase IV

The mechanism focuses on the inhibition of two bacterial enzymes, DNA Gyrase (Topoisomerase II) and Topoisomerase IV, which manage the structure and separation of the bacterial chromosome. The drug exhibits a differential affinity for these microbial enzymes over their human counterparts, resulting in a selective toxicity profile. The resulting physiological effect is the breakdown of the bacterial cell's fundamental processes, leading to cell death.


Inducing Lethal Genomic Damage (Bactericidal Cascade)

The core mechanism involves a biological cascade where the drug stabilizes the enzyme-DNA complex in a cleaved state, leading to the formation of double-strand DNA breaks. This process leads to a bactericidal (cell-killing) action, as opposed to a bacteriostatic one. The resulting physiological consequence is the death of the target bacterial cells. The mechanism is constrained by bacterial resistance, such as mutations in the enzyme structure or the expression of efflux pumps.

Dosage and Administration Information

Syran (Ciprofloxacin) is administered via multiple routes depending on the required usage. For systemic treatment, the medicine is delivered through oral forms, which include Immediate-Release tablets, Extended-Release tablets, or an oral suspension, or by intravenous (IV) infusion. Localized infections are addressed using dedicated ophthalmic (eye) or otic (ear) preparations.

Dosing regimens typically dictate that Immediate-Release oral forms are administered twice daily (every 12 hours) in adult doses ranging from 250 mg to 750 mg. The Extended-Release tablet formulation, however, is utilized once daily (every 24 hours). The total duration of therapy is dependent on the regimen and can range from short courses of 3 days for specific uncomplicated infections up to 60 days for certain post-exposure prophylaxis protocols.

Administration requires specific procedural compliance to ensure proper absorption. Oral formulations must be separated by at least 2 hours before or 6 hours after consuming products that contain multivalent metal cations, such as antacids or supplements containing iron, calcium, and zinc. This separation prevents reduced absorption of the drug. Furthermore, the oral forms should not be taken solely with dairy products (e.g., milk, yogurt) or calcium-fortified juices.

Dose adjustments are a required component of use for certain patient populations. Dosing intervals or total amounts must be modified for adult patients exhibiting renal impairment (reduced kidney function). If the medicine is delivered intravenously, the solution is infused slowly over a period of approximately 60 minutes.

Recent Clinical Evidence

Research evidence / Overview of studies for Syran

Evidence from Trials for Treating Urinary Tract Infections

The research exploring Syran for urinary tract infections (UTIs), including complicated and uncomplicated forms, involves many trials, primarily based on Randomized Controlled Trials (RCTs) and formal Systematic Reviews. Studies examined how Syran compares to other established treatments. The focus of these trials was on outcomes related to clinical response (such as the resolution of symptoms related to physical discomfort) and the measurement of bacterial load, which monitors the level of problematic bacteria.

Research findings described patterns observed where the measured outcomes for symptom resolution and bacterial load measurement were evaluated against other compounds in the same class. The studies typically involved a short-term observation period, usually lasting one to two weeks.

Evidence from Studies on Respiratory and Systemic Infections

Syran was studied for a range of other bacterial infections, including those affecting the lower respiratory tract, the skin and soft tissues, and bone and joint infections. For acute respiratory infections, trials monitored outcomes such as the measurement of clinical response. For patients with chronic lung conditions, such as NCFB, research explored whether the inhaled formulation was associated with a measured change in the frequency of exacerbations over an extended time interval.

Research for bone and joint infections, which are often challenging to study, utilized a mix of RCTs and observational settings. These studies explored long-term outcomes and the monitoring of relapse rates over follow-up periods that can be significantly longer—sometimes lasting several weeks or months.

Gaps and Areas of Scientific Uncertainty

Scientific literature and regulatory assessments are transparent about areas where knowledge concerning Syran is still developing. A major recognized area of uncertainty is the increasing global trend of pathogen resistance, which may influence future scientific findings for this compound. Furthermore, data for certain groups remain insufficient, particularly for patients with highly complex medical backgrounds or rare disease subtypes, where sample sizes were modest in the available research. Since most studies examine acute symptom changes, long-term effects are not fully established, and future research is needed to provide deeper insight into functional status.

Key Studies & References

  1. Ciprofloxacin Drug Information (U.S. National Library of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Syran (FAQ)


Q: Can Syran be taken by older adults?

A: Official information notes that older adults, particularly those over 60, have an officially recognized increased risk for certain severe side effects. This includes a higher risk for tendon problems and changes to heart rhythm, specifically QT interval prolongation. Regulatory labeling notes that careful monitoring for these risks is generally considered necessary when the medicine is used in this age group.


Q: Can Syran be used during pregnancy, based on official information?

A: The safety and effectiveness of Syran in pregnant women have not been established through dedicated human studies. Based on findings from animal studies, the drug is generally not recommended for use during pregnancy. This is due to a potential for adverse effects on the developing joint cartilage.


Q: Can Syran be used while breastfeeding, according to official guidance?

A: Official guidance states that Syran is excreted in breast milk. Due to the potential risk of damage to the baby's developing joints (articular damage), official labeling generally advises against its use during the breastfeeding period. This guidance reflects the regulatory stance based on observed potential risks.


Q: Does Syran affect blood pressure or heart rate?

A: Official safety data indicates Syran and other drugs in its class have been associated with prolongation of the QT interval. This is a measure of the heart's electrical rhythm. Regulatory documents indicate that avoidance of the medication is recommended for patients with known QT prolongation to manage the potential cardiovascular risk.


Q: What if Syran seems less effective after using it for a while?

A: The core function of Syran is constrained by the biological process of bacterial resistance. Official research notes that an increasing global trend of pathogen resistance is a recognized area of scientific uncertainty. This development may influence the drug's effectiveness over time.


Q: Is Syran safe for long-term use?

A: Regulatory warnings highlight the risk of certain serious side effects, such as tendinitis/tendon rupture and peripheral neuropathy (nerve damage), which can occur months after treatment and may be potentially irreversible. The lack of established long-term data indicates that future research is needed to provide deeper insight into its sustained use.


Q: Do the side effects of Syran usually go away over time?

A: Official warnings note that while many common side effects may be temporary, certain serious adverse reactions, specifically tendon rupture and peripheral neuropathy (nerve damage), have been reported in regulatory documents as potentially irreversible.


Q: Can Syran affect my mood or mental state?

A: Yes, official documents describe that Syran has been associated with Central Nervous System (CNS) side effects. Reported symptoms include agitation, confusion, depression, and hallucinations. Psychotic reactions have also been reported, though less frequently.


Q: How long does it typically take to start feeling the effects of Syran?

A: Based on pharmacokinetic studies, which track the drug's journey in the body, the maximum concentration of Syran in the blood is generally reached approximately one to two hours after taking an oral dose.


Q: What is the expected duration of Syran's effects after taking it?

A: The drug's official half-life (the time required for its concentration to drop by half) is approximately 4 hours in patients with normal kidney function. The active drug is virtually completely excreted from the body within 24 hours.


Q: Is Syran a narcotic or a controlled substance?

A: Syran (Ciprofloxacin) is a prescription antibiotic used to eliminate bacterial infections. It is not classified as a controlled substance or narcotic by official regulatory agencies.


Q: Is there a risk of becoming dependent on Syran?

A: As Syran is an antibiotic and not classified as a controlled substance, official sources do not indicate a risk of physical or psychological dependence associated with its use.


Q: Is there a generic version of Syran available?

A: Yes, the active ingredient in Syran is Ciprofloxacin, which is widely available as a generic medication. Generic availability is confirmed by official drug reference resources.


Q: What is the difference between the brand name Syran and its generic form?

A: The generic version contains the same active ingredient (Ciprofloxacin) in the same amount and is required to meet the same official quality and performance standards as the brand name product. Regulatory agencies require generic forms to demonstrate therapeutic equivalence to the brand name product.


Q: Is it normal to feel a certain way when first starting Syran?

A: Official records show that common side effects, such as nausea and diarrhea, are frequently reported by users when starting the medication. Some patients may also report initial symptoms related to the nervous system, such as dizziness.


Q: Why do some people experience initial side effects with Syran?

A: Side effects are expected physiological reactions that occur during exposure to any drug. Common adverse reactions like nausea and diarrhea are listed in official documents as reactions that affect a notable percentage of users as their body adjusts to the medication.


Q: Does Syran affect my sleep patterns?

A: Official documents list insomnia (difficulty sleeping) as a reported side effect associated with the use of Syran. This is considered one of the potential side effects related to the Central Nervous System (CNS).


Q: What is the recommended age range for people who can use Syran?

A: Syran is generally indicated for adult patients for most uses. Official labeling advises caution or avoidance for pediatric patients (under 18) due to an increased incidence of adverse effects related to joints and surrounding tissues in this age group.


Q: Is there any official information about Syran and alcohol consumption?

A: Official regulatory documents typically do not list alcohol as a specific contraindication requiring absolute avoidance. However, consuming alcohol may potentially worsen common reported side effects of the drug, such as nausea, dizziness, or headache.


Q: What are the conditions under which Syran should be discontinued?

A: Official warnings describe that Syran is generally intended to be discontinued immediately if signs of a serious adverse reaction occur. This includes symptoms of tendon pain or rupture or serious Central Nervous System effects, such as seizures or severe confusion.


Q: Does Syran affect laboratory test results?

A: Official labeling notes that Syran may interfere with certain laboratory tests. For instance, it may cause a false-positive result for opioids on some urine screening tests. It is generally described in official information that patients may need to inform laboratory personnel they are taking the medication.


Q: Is it necessary to take Syran at the exact same time every day?

A: Syran is typically prescribed for administration in regimens such as 'twice daily (every 12 hours)'. Following the prescribed timing consistently is important to ensure the drug concentration needed to eliminate the bacteria is maintained throughout the treatment period.


Q: Is Syran effective for everyone who uses it?

A: Official research notes that bacterial resistance is a recognized factor that may influence the drug's effectiveness. The core section also notes that data for patients with complex medical backgrounds is limited, implying the response can vary between individuals.


Q: Do children use Syran?

A: Official labeling states that Syran should be avoided in pediatric patients (under 18) for most infections. This is due to an officially recognized increased incidence of adverse effects related to joints and surrounding tissues.

How should Syran be stored and disposed of?

How to Store and Dispose of Syran

Storage and disposal must strictly follow the requirements documented in official regulatory labeling for Syran (Ciprofloxacin) to maintain product stability and ensure safety.

Storage Conditions

Syran tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F to 77 F), away from excessive heat and moisture. The medicine must be kept in its original container and the container must remain tightly closed. It is mandatory to keep the product out of the sight and reach of children.

  • Do not freeze any form of the product.
  • Reconstituted oral suspension must be discarded after 14 days.

Disposal Instructions

Expired or unused Syran must be disposed of using a drug take-back program as the preferred method. If a take-back is unavailable, the medicine should be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a container, and placed in the household trash. Do not flush Syran down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Syran found in:

A-Z Index: